

January 4, 2013

Completion of a transfer of business involving consolidated subsidiary Hematech, Inc.

Tokyo, Japan, January 4, 2013 --- Kyowa Hakko Kirin Co., Ltd. (President and CEO: Nobuo Hanai, “Kyowa Hakko Kirin”) hereby announces that it has resolved to transfer operations related to fully human antibody-producing bovine carried out by consolidated subsidiary Hematech, Inc^{*1} (Headquarters: Sioux Falls, SD, USA, CEO: Eddie J. Sullivan, “Hematech”) to Sanford Applied Biosciences, LLC^{*2} (Sioux Falls, SD, USA, “Sanford”) and that a transfer of business agreement had been concluded between Hematech and Sanford. Under this agreement, the target business was transferred from Hematech to Sanford on December 31, 2012.

This transfer of business will have a minimal effect on the performance of Kyowa Hakko Kirin.

*1. About Hematech:

Hematech is a company established in 1998 that possesses the technology to produce bovines in which fully human antibodies can be generated. It became a subsidiary of the (then) Pharmaceutical Division of Kirin Brewery in 2005 and has been a wholly owned subsidiary of Kyowa Hakko Kirin since Kyowa Hakko Kirin’s establishment.

*2. About Sanford:

Sanford Health, a non-profit organization headquartered in North Dakota and South Dakota that runs integrated medical systems, was established in Sioux Falls, SD, USA.